Toxoplasmosis is a common infection whose clinical severity can sometimes justify admission to intensive care, especially in immunocompromised patients.
This study should make it possible to evaluate the impact of different anti-infective treatment regimens and to highlight clinical-biological and prognostic differences depending on the type of underlying immunosuppression.
Adult patient hospitalized in intensive care
At least 1 organ failure (SOFA> or =2)
PCR toxoplasmosis on CSF, blood, BAL, or bone marrow positive within 7 days before or after admission to ICU
Post-mortem diagnosis
Primary outcome not available
Patient living informed and not opposed to the reuse of their data in this research.
Patients hospitalized in intensive care for toxoplasmosis (positive toxoplasmosis PCR) between 2012 (01/01/2012) and 2023 (02/01/2023)
Other
Retrospective
Not listed
Mortality rate in intensive care.
The aim is to determine the impact of the anti-infective treatment regimen used on the prognosis of patients with severe toxoplasmosis in intensive care.
Hospital mortality rate
Length of stay in intensive care
Duration of mechanical ventilation
Click on the lead sponsor to view all of their trials.
